Agile market access

The market access in Germany is and remains one of the biggest and most important challenges for the pharmaceutical industry. The system is extremely complex: the smallest decisions on chosen paths can have significant implications for the direction and potential overall success. In addition, the system itself is also subject to inherent changes that pharmaceutical entrepreneurs (pU) are often confronted with unprepared during their individual missions. Fortunately, it has been proven that agile working can lead to significant efficiency and outcome improvements despite the multi-layered and complex challenges of market access for drugs & ATMPs (advanced therapy medicinal products).